News & Media

RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com.

Press Releases

All Verastem Oncology press releases are archived here.

Media Resources

Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers. These types of cancers—which include low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are extremely difficult to treat and currently available therapeutic options are limited and suboptimal. That’s why new options are needed, and we’re committed to delivering them.

 

For media interested in Verastem Oncology, please contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com. You can also refer to the resources below, which contain information about what we do, our leadership team and our financials.

 

 

To stay updated on the latest news about Verastem Oncology, sign up for alerts.

Previous and Upcoming Events

Below are past or scheduled upcoming events either hosted or sponsored by Verastem Oncology.

Articles Featuring Verastem Oncology

Contact

Lisa Buffington
Corporate Communications
(781) 292-4502
media@verastem.com

Tweets by @VerastemOncolog

$VSTM is honored to be the presenting regional sponsor for #TogetherInTEAL with @NOCC_National as we break the silence on #OvarianCancer at this year’s Everywhere as ONE celebration being broadcast nationally this Sat. at 7pm EDT. #KnowOvarian #NOCCEA1 https://bit.ly/3AF7azP

Today we unveiled Verastem Oncology's new brand that reflects the purpose and the urgency behind ensuring no cancer patient ever runs out of options. Check out our website to learn more. #CancerResearch #oncology